Cablevision's support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research.

Research Awards Listing

Research follows dollars, and The Lustgarten Foundation believes that increasing funds for pancreatic cancer research will translate into enhanced patient care, and ultimately, a cure.

The Lustgarten Foundation firmly believes that increasing funds for pancreatic cancer research is the surest path to improved patient care and eventually, to a cure. To date, we have committed nearly $110 million to providing the best and brightest minds with the resources to pursue the study and eradication of the disease.

View Award Listings by Year

2014  |  2013  |  2012  |  2011  |  2010  | 2009  |  2008  | 2007  |  2006  |  2005  |  2004  |  2003  |  2002  |  2001  |  2000-1998

2006 Research Grants

Dana-Farber Cancer Institute
David Frank, M.D., Ph.D.
Inhibition of STAT3 in the Targeted Therapy of Pancreatic Cancer

Johns Hopkin Medical Institutions
Marcia Canto, M.D.
Screening for Early Pancreatic Neoplasia: A Multicenter Study

Johns Hopkins Medical Institutions
James Eshleman, M.D., Ph.D.
Pancreatic Cancer Tumor Suppressor Gene Discovery using RNAi

Johns Hopkins Medical Institutions
Elizabeth Jaffee, M.D.
Identification and Analysis of New Pancreatic Antigens as Targets of the Immune Response

Johns Hopkins Medical Institutions
Anirban Maitra, MBBS
Synergistic Targeting of the Apoptotic Machinery in Pancreatic Cancer

Johns Hopkins Medical Institutions
Bert Vogelstein, M.D.
Sequencing the Pancreatic Cancer Genome

Purdue University
David Konieczny, Ph.D.
Mist 1 Kras G12D Generated Pancreatic Cancer

Salk Institute for Biological Studies
Inder M. Verma, Ph.D.
A Novel Mouse Model of Pancreatic Cancer Using Lentiviral Vectors

Samuel Lunenfeld Research Institute
Steven Gallinger, M.D.
Characterization of Germline DNA Copy Number Variation in Familial Pancreas Cancer

University of California at San Francisco Comprehensive Cancer Center
Martin McMahon, Ph.D.
Targeting Kinases to Overcome Gemcitabine Resistance in Pancreatic Carcinoma

University of Texas M.D. Anderson Cancer Center
George Halder, Ph.D.
A Novel Genetic System to Identify Ideal Cancer Drug Targets in Pancreatic Cancer

2015 website development and design sponsored by Celgene

1111 Stewart Avenue, Bethpage, New York 11714
Toll Free: 1-866-789-1000 P: 516-803-2304 F: 516-803-2303